Clinical trial · Observational
The Level of Patient Participation in Lung and Esophageal Cancer Patients Treated With Definitive Radiochemotherapy.
A Prospective Observational Study on the Level of Patient Participation in Lung and Esophageal Cancer Patients Treated With Definitive Radiochemotherapy.
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study aims to assess the level of participation of thoracic cancer patients undergoing definitive radiotherapy and chemotherapy ± immunotherapy in their medical processes and the association between the level of participation and patients' side effects, quality of life, and long-term survival. Additionally, this study will rate the level of participation from both the patients' and medical staff's perspectives and will compare the differences in ratings from these two viewpoints, as well as their impact on treatment outcomes.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Esophageal Cancer | Malignant Esophageal Neoplasm | CURATED_EXACT | 0.92 |
| Lung Cancer | Malignant Lung Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (0)
Data not yet available
Design
Arms and outcomes
Arms (1)
- label
- Observational group
- description
- Patients undergoing definitive radiochemotherapy ± immunotherapy will be assessed about the level of participation in their medical processes.
Primary outcomes (1)
- measure
- Incidence of >=Grade 3 toxicities
- timeFrame
- 2 years
- description
- The percentage of patients who develop \>=Grade 3 toxicities
Secondary outcomes (2)
- measure
- Overall survival
- timeFrame
- 2 years
- description
- 2-year survival rate
- measure
- Progression-free survival
- timeFrame
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 75 Years
Show eligibility criteria text
Inclusion Criteria: * Locally advanced non-small cell lung cancer, limited-stage small cell lung cancer, and esophageal cancer. * Planned to undergo definitive chemoradiotherapy ± immunotherapy; * Males or females aged 18 to 75; * Able to communicate with medical staff. Exclusion Criteria: Patients with cognitive impairments.
References
Publications (0)
Data not yet available